India grants first compulsory licence

No items found.
​
March 14, 2012
No items found.
Table of contents
  • Toc Heading
  • Toc Heading

The first compulsory licence has been granted by the Controller of Patents Mumbai.

The application concerns the anti-cancer drug Sorafenib, a patented drug owned by Bayer Corporation. The applicant for a compulsory licence is Natco Pharma Limited, an Indian generic pharmaceuticals company.

Darren Smyth's post on the IPKat explores the implications of this landmark decision.

Recent Case Reports

See all Case Reports

Seriously deficient disclosure process not sufficient to reopen costs order - Cabo v MGA
08 April 2026
A High Court decision highlighting the consequences of inadequate disclosure searches under PD57AD and reaffirming that costs orders are final, even where later failures come to light.
​
UPC Court of appeal issues final decision, despite no finding on infringement at first instance
30 March 2026
In Rematec v Europe Forestry, the UPC Court of Appeal overturned the Mannheim Local Division’s revocation of the patent and, applying Article 75(1) UPCA, issued a final decision on both validity and infringement despite no infringement finding at first instance. The Court adopted a narrower, description‑led approach to claim interpretation, confirmed the patent’s validity, found infringement, and granted final remedies without referring the case back to the Court of First Instance.
​
Litigation insurance as security for costs
30 March 2026
In Syntorr v Arthrex, the UPC Court of Appeal clarified that while litigation insurance is not itself a form of security under Rule 158 RoP, it is a relevant factor when deciding whether security for costs should be ordered at all. By failing to consider the claimant’s insurance policy, the Munich Local Division wrongly exercised its discretion. The Court set aside the €2 million security order and confirmed that insurance can mitigate concerns about cost recoverability.
​